UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  September 8, 2009

 

AFFYMAX, INC.

(Exact name of registrant as specified in charter)

 

Delaware

 

001-33213

 

77-0579396

(State or other jurisdiction of

 

(Commission File Number)

 

(I.R.S. Employer Identification No.)

incorporation)

 

 

 

 

 

4001 Miranda Avenue
Palo Alto, California 94304
(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (650) 812 - 8700

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

o

Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

 

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 8.01. Other Events.

 

On September 8, 2009, Affymax, Inc. (the “Company”) notified clinical trial sites to complete treatment of patients in the Phase 3 clinical program for the investigational drug, Hematide™, by the end of 2009.  A press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01. Financial Statement and Exhibits.

 

(d)                     Exhibits:

 

Exhibit
No.

 

Description

 

 

 

99.1

 

Press Release entitled “Affymax Provides Phase 3 Program Update for Investigational Drug, Hematide™ , to Treat Anemia in Chronic Renal Failure,” dated September 9, 2009.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

AFFYMAX, INC .

 

 

 

Dated: September 9, 2009

By:

/s/ Paul B. Cleveland

 

 

 

 

 

Paul B. Cleveland
Executive Vice President,
Corporate Development and Chief Financial Officer

 

3


 

EXHIBIT INDEX

 

Exhibit
No.

 

Description

99.1

 

Press Release entitled “Affymax Provides Phase 3 Program Update for Investigational Drug, Hematide™ , to Treat Anemia in Chronic Renal Failure,” dated September 9, 2009.

 

4